Latest Oncology News

Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis

December 15th 2025

Kristi Rosa

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Revumenib Shows Activity Across R/R KMT2A-Rearranged Acute Leukemia Subtypes

December 15th 2025

Kyle Doherty

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Five Under 5: Top Oncology Videos for the Week of 12/7

December 14th 2025

OncLive Staff

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

Talquetamab Plus Pomalidomide Maintains Deep, Durable Responses in R/R Multiple Myeloma

December 14th 2025

Russ Conroy

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

DREAMM-8 Study Triplet Sustains PFS, MRD-negativity in R/R Multiple Myeloma

December 14th 2025

Tim Cortese

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

Latest Oncology Videos

NSCLC Case Study 2: A Never-Smoker with Neuroendocrine Markers

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Mayer on Efficacy Findings With Giredestrant Plus Everolimus in ER+/HER2– Advanced Breast Cancer

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Deciphering Biomarker Results for Adjuvant Immunotherapy in NSCLC

Improving Workflow and ctDNA Adoption in MIBC Care

The Role of DNA & RNA in Comprehensive Genomic Profiling

Challenges in Standardizing ctDNA-guided MRD Testing in MIBC

PD-L1 Testing in NSCLC: A Practical Guide for Oncologists

Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC

Dr Gonzalez-Martin on the Safety of TUB-040 in Ovarian Cancer

Multidisciplinary Collaboration to Improve Early Recognition and Care For CA-LEMS

NCCN Guidelines and Management of CA-LEMS in the Practice

Monitoring and Optimizing Treatment Response in LEMS Management

Dr Yap on Saruparib/Camizestrant in Advanced ER+, HER2-Negative or HER2-Low Breast Cancer

Antibody-Based Strategies and the Role of R2 in Relapsed Follicular Lymphoma

Ongoing Research to Watch at ASH 2025 and Beyond

Role of BRAF Mutations in NSCLC

Endometrial Cancer: Broadening Therapeutic Options in pMMR - Insights from DUO-E/AtTEnd

Other Possible Research Avenues for Blinatumomab in ALL

Patient Profile and Treatment Selection in ALK+ NSCLC

IMvigor011: A Phase 3 Trial of Circulating Tumour (ct)DNA-Guided Adjuvant Atezolizumab vs Placebo in Muscle-Invasive Bladder Cancer

All Oncology News

Treatment Strategies for CA-LEMS

December 12th 2025

Wade T. Iams, MD

Oncologists explore the challenges of distinguishing between chemotherapy fatigue and cancer-related limb pain, emphasizing the need for effective screening tools.

Selecting Second-Line Therapy: Balancing Targets, Toxicities, and Durability

December 12th 2025

Amitkumar Mehta, MD

Segment III explores how clinicians approach second-line therapy in follicular lymphoma, particularly as new options challenge traditional standards. Dr. Mehta reviews how CD20-directed therapies have historically anchored relapse treatment but notes the shift toward more diverse targets, including CD3 (via bispecific antibodies) and CD19 (via tafasitamab and other emerging agents). This expansion raises important clinical questions around target sequencing, resistance, and whether using a target early may “burn” it for future lines of therapy. The discussion highlights the role of bispecific antibodies, CAR T-cell therapy, and CD19-based agents, along with practical considerations such as infusion requirements, monitoring demands, and access to treatment centers with specialized capabilities. Dr. Mehta explains how academic-community partnerships influence real-world treatment pathways, especially for therapies with more complex toxicity profiles like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). NP Bailey contributes perspective on patient logistics, including distance to treatment centers, social support needs, and how the complexity of treatment may shape patient decision-making. She emphasizes the importance of aligning therapy selection with patient lifestyle and functional status, a theme that recurs throughout the program. This segment underscores the increasingly individualized nature of second-line therapy, where clinicians must integrate disease biology, treatment history, patient comorbidities, and practical feasibility. As the faculty outline, modern management requires balancing efficacy with safety, accessibility, and long-term planning, ensuring that patients receive not only effective but sustainable care.

Endometrial Cancer: An Integrated View of LEAP-001, KEYNOTE-775, RUBY and NRG-GY018 for Treatment Strategy

December 12th 2025

Nicoletta Colombo, MD, PhD

Panelists discuss how comparing LEAP-001, KEYNOTE-775, RUBY, and NRG-GY018 helps position lenvatinib plus pembrolizumab mainly after chemotherapy (or when chemo isn’t feasible) while reinforcing chemo–PD-1 combinations—especially in dMMR disease.

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer

December 12th 2025

Riley Kandel

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer

December 12th 2025

Caroline Seymour

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer

December 12th 2025

Courtney Flaherty

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

Alpelisib Plus Fulvestrant Hits Primary PFS End Point in CDK4/6 Inhibitor–Pretreated, PIK3CA-Mutant, HR+/HER2– Breast Cancer

December 12th 2025

Kyle Doherty

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.

CAPItello-291 Analysis Reveals Potential Utility of PIK3CA/AKT1/PTEN Alteration Detection Via ctDNA in Advanced HR+ Breast Cancer

December 11th 2025

Chris Ryan

Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.

Less Invasive Axillary Staging Yields Noninferior 3-Year Axillary RFS vs ALND in Node-Negative Breast Cancer

December 11th 2025

Andrea Eleazar, MHS

Axillary RFS at 3 years was noninferior with less vs more invasive staging procedures in node-negative breast cancer after neoadjuvant chemotherapy.

Oral and Subcutaneous Azacitidine Show Comparable PK, Safety Profiles in MDS and CMML

December 11th 2025

Bridget Hoyt

Oral azacitidine demonstrated a similar pharmacokinetic and safety profile to the subcutaneous formulation in MDS or CMML.

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

December 11th 2025

Ursula A. Matulonis, MD

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

Dr Punie on Patient-Reported Outcomes With Sacituzumab Govitecan vs Chemotherapy in Advanced TNBC

December 11th 2025

Kevin Punie, MD, PhD

Kevin Punie, MD, discusses PRO data from the phase 3 ASCENT-03 trial.

Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC

December 11th 2025

Riley Kandel

Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.

Dr Rugo on Elacestrant-Based Combos in ER+/HER2– Locally Advanced or Metastatic Breast Cancer

December 11th 2025

Hope S. Rugo, MD

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Resection of MRI-Detected Disease Fails to Improve Recurrence Rates in Early Breast Cancer

December 11th 2025

Tim Cortese

Locoregional recurrence-free rates were similar in newly diagnosed breast cancer, irrespective of resection of MRI-detected disease.

See All News